While we all roll up our sleeves for a full reopening, let’s spring into this month’s selection of noteworthy news:
- Thoughts on Cigna’s payments to patients for non-medical switching
- 340B’s explosive specialty pharmacy growth
- An excellent analysis of GoodRx
Plus, my $0.02 on U.S. drug pricing policy.
P.S. Join the more than 11,600 followers of my daily links to neat stuff at @DrugChannels on Twitter. Recent posts have covered biosimilars, pharmacist workloads, formularies, pricing, PSAOs, Part D spending, copay accumulators, H.R.3, and more. You can also join my more than 17,000 followers on LinkedIn.
Read more »
Source: Post feed
